期刊文献+

原发性高血压患者脂蛋白相关磷脂酶A2浓度水平及临床意义的研究 被引量:3

Concentration of Lipoprotein- associated Phospholipase A2 in Blood Plasma and Its Clinical Significance in Patients with Essential hypertension
在线阅读 下载PDF
导出
摘要 目的观察高血压患者血浆中脂蛋白相关磷脂酶A2(LP-PLA2)水平,探讨它与EH的关系及其临床意义。方法选择原发性高血压病患者120例。按临床诊断分为:1级30例,2级43例,3级47例;又据危险分层分为:低中危组33例,高危组38例,极高危组49例;健康对照组40例,测定脂蛋白相关磷脂酶A2(LP-PLA2),并记录高敏C反应蛋白(hs-CRP)、血脂等临床指标。结果高血压组LP-PLA2水平显著高于对照组,极危组中LP-PLA2水平显著高于高危组和低中危组,差异有统计学意义(P<0.01);LP-PLA2与危险分层、收缩压、舒张压、低密度脂蛋白胆固醇(LDL-C)呈显著的正相关(P<0.05)。结论外周血浆中LP-PLA2水平随血压的升高而升高,它可能参与了高血压的发生、发展过程。 Objective To observe the level of LP-PLA2 in the plasma of patients with hypertension,and to explore its relationship with EH and its clinical significance.Methods Totally 120 EH patients were selected and graded by clinical diagnosis:stage Ⅰ 30 cases,stage Ⅱ 43 cases,stage Ⅲ 47 cases; graded by risk stratification:low-risk group 33 cases,high-risk group 38 cases,very high-risk group 49 cases.Forty cases were in the control group.Lipoprotein-associated phospholipase A2 (LP-PLA2),high-sensitivity C -reactive protein (hs-CRP),lipids and other clinical parameters were detected.Results LP-PLA2 of hypertension group were significantly higher than that in the control group,and LP-PLA2 of very high-risk group were significantly higher than that in high-risk group and low-risk group (P 〈 0.01).LP-PLA2 showed a significant positive correlation with risk stratification,systolic blood pressure,diastolic blood pressure,and low-density lipoprotein cholesterol (LDL-C) (P 〈 0.05).Conclusion LP-PLA2 in peripheral blood increased with the severity of hypertension.It may be involved in the occurrence and development of hypertension.
出处 《医学研究杂志》 2013年第9期147-149,共3页 Journal of Medical Research
关键词 高血压 磷脂酶A2 危险因素 炎症 Hypertension Phospholipase A2 Risk Factors Inflammation
作者简介 通讯作者:刘丽娟,电子信箱:gzq123xyz@126.com
  • 相关文献

参考文献11

  • 1Daly C A, Hildebrandt P, Bertrand M, et al. Adverse prognosis asso- ciated with themetabolic syndrome in established coronary artery dis- ease, data from the EUROPA trial[ J ]. Heart,2007,93 ( 11 ) : 1406 - 1411.
  • 2Varpula M, Pulkki K, Karlsson S, et al. Predictive value of Ntermi- nal pro - brain rmtrluretle peptide in severe sepsis and septic shock [ J ]. Crit Care Med,2007,35 ( 5 ) : 1277 - 1283.
  • 3朱毓,吴美华.脂蛋白相关磷脂酶A_2与动脉粥样硬化性疾病[J].心脏杂志,2008,20(1):101-103. 被引量:5
  • 4郝喜娃,李月春,刘国荣,王宝军.脂蛋白相关磷脂酶A2的影响因素及其研究价值[J].国际脑血管病杂志,2010,18(1):59-61. 被引量:5
  • 5单红英,刘春霞,秋冬梅,李海涛.缬沙坦对高血压合并糖耐量异常患者一氧化氮和炎症因子影响[J].心血管康复医学杂志,2011,20(2):160-162. 被引量:12
  • 6Krishnankutty S. Lipoprotein -associated phospholipase A2, vascular inflammation and cardiovascular risk prediction [ J ]. Vascular Health and Risk Management,2006,2 ( 2 ) : 153 - 156.
  • 7Puddu P, Puddu GM, Cravero E, et al. The molecular sources of re- active oxygen species in hypertension[J]. Blood Press,2008,17 (2) : 70 -77.
  • 8Lavi S, McConnell JP,Rihal CS,et al. Local production of lipoprotein -associated phospholipase A2 and lyso -phosphatidylcholine in the coronary circulation:association with early coronary atherosclerosis and endothelial dysfunction in humans [J]. Circulation ,2007,115:2715 - 2721.
  • 9Watson T, Gooo PK, Lip GY. Endothelial progenitor cells endothelial dysfunction inflammationt and oxidative stress in hypertension [ J ]. Antioxid Redox Signal,2008,10 ( 6 ) : 1079 - 1088.
  • 10Escobar E. Hypertension and coronary heart disease[ J]. Hum Hyper- tens,2002,16 : s61 - s63.

二级参考文献36

  • 1陈月云,章辉,朱正才,王德国,张平洋.阿托伐他汀对不同血脂水平的高血压病患者血管内皮功能的影响[J].高血压杂志,2005,13(2):88-92. 被引量:19
  • 2亓鹏.2004年中国高血压防治指南(实用本)及新特点[J].解放军保健医学杂志,2005,7(4):248-251. 被引量:13
  • 3Oei HH, van der Meer IM, Hofman A, et al. Liporotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation, 2005,111: 570-575.
  • 4Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta, 2000, 1488: 1-19.
  • 5Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 1999, 19: 2909-2017.
  • 6Tsimihodimos V, Karabina SA, Tambaki AP, et al. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res, 2002, 43: 256-263.
  • 7Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nattre, 1995, 374: 549-553.
  • 8Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2 : a risk marker or a risk factor? Am J Cardiol, 2008, 101 (12A): 11F- 22F.
  • 9Samanta U, Wilder C, Bahnson BJ. Crystallization and preliminary X-ray crystallographic analysis of human plasma platelet activating factor acetylhydrolase. Protein Pept Lett, 2009, 16: 97-100.
  • 10Rosenson RS, Vracar-Grabar M, Helenowsld I. Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids. Cardiovasc Drugs Ther,2008,22: 55 -58.

共引文献48

同被引文献11

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部